Aspirin induces apoptosis in oesophageal cancer cells by inhibiting the pathway of NF-kappaB downstream regulation of cyclooxygenase-2

ANZ Journal of Surgery

Volumn 75, Issue 11, 2005, Pages 1011-1016

  Liu, Jun Feng ^a   Jamieson, Glyn G ^b   Drew, Paul A ^c   Zhu, Gui Jun ^a   Zhang, Shao Wei ^a   Zhu, Tie Nian ^a   Shan, Bao En ^a   Wang, Qi Zhang ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

Apoptosis; Aspirin; COX 2; Cyclooxygenase; NF kappaB; NSAIDs; Oesophageal cancer; Oesophageal squamous cell carcinoma; Tumour cells cultured

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; MEMBRANE PROTEIN; PTGS2 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PREVENTION; CELL LEVEL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; CYTOPLASM; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; NITROBLUE TETRAZOLIUM TEST; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BIOSYNTHESIS; CELL DIVISION; CELL NUCLEUS; CHEMISTRY; ESOPHAGUS TUMOR; METABOLISM; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

APOPTOSIS; ASPIRIN; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL LINE, TUMOR; CELL NUCLEUS; CYCLOOXYGENASE 2; CYTOPLASM; ESOPHAGEAL NEOPLASMS; HUMANS; MEMBRANE PROTEINS; NF-KAPPA B; PROSTAGLANDINS; RNA, MESSENGER;

EID: 33644874116     PISSN: 14451433     EISSN: 14452197     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2005.03596.x     Document Type: Article

References (36)

1. Parkin DM Pisani P Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer 1999 80 : 827 41.
2. Lerut T. Oesophageal carcinoma: past and present studies. Eur. J. Surg. Oncol. 1999 22 : 317 23.
3. Kok TC Tilanus HW. Neoadjuvant treatment in oesophageal cancer: the needs for future trials. The Rotterdam Esophageal Tumor Study Group. Eur. J. Surg. Oncol. 1999 22 : 323 5.
4. Becker HD. Esophageal cancer, early disease: diagnosis and current treatment. World J. Surg. 1994 18 : 331 8.
5. Liu JF Wang QZ Hou J. Surgical treatment for cancer of the oesophagus and gastric cardia in Hebei, China. Br. J. Surg. 2004 91 : 90 8.
6. Farrow DC Vaughan TL Hansten PD et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomarkers Prev. 1998 7 : 97 102.
7. Funkhouser EM Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995 76 : 1116 19.
8. Li M Lotan R Levin B Tahara E Lippman SM Xu XC. Aspirin induction of apoptosis in esophageal cancer: a potential for chemoprevention. Cancer Epidemiol. Biomarkers Prev. 2000 9 : 545 9.
9. Corley DA Kerlikowske K Verma R Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003 124 : 47 56.
10. Wilson KT Fu S Ramanujam KS Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res. 1998 58 : 2929 34.
11. Zimmermann KC Sarbia M Weber AA Borchard F Gabbert HE Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 1999 59 : 198 204.
12. France M Drew PA Dodd T Watson DI. Cyclo-oxygenase-2 expression in oesophageal adenocarcinoma as a determinant of clinical outcome following esophagectomy. Dis. Esophagus 2004 17 : 36 40.
13. Xu XC. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anticancer Drugs 2002 13 : 127 37.
14. Zha S Yegnasubramanian V Nelson WG Isaacs WB De Marzo AM. Cyclooxygenases in cancer: progress and perspective. Cancer Lett. 2004 215 : 1 20.
15. Xu XM Sansores-Garcia L Chen XM Matijevic-Aleksic N Du M Wu KK. Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc. NatlAcad. Sci. U S A 1999 96 : 5292 7.
16. Lim JW Kim H Kim KH. Nuclear factor-kappaB regulates cyclooxygenase-2 expression and cell proliferation in human gastric cancer cells. Lab. Invest. 2001 81 : 349 60.
17. Gallois C Habib A Tao J et al. Role of NF-kappa B in the antiproliferative effect of endothelin-1 and tumor necrosis factor-alpha in human hepatic stellate cells. Involvement of cyclooxygenase-2. J. Biol. Chem. 1998 273 : 23183 90.
18. Kojima M Morisaki T Izuhara K et al. Lipopolysaccharide increases cyclo-oxygenase-2 expression in a colon carcinoma cell line through nuclear factor-kappa B activation. Oncogene 2000 19 : 1225 31.
19. Liu S Khemlani LS Shapiro RA et al. Expression of CD14 by hepatocytes: upregulation by cytokines during endotoxemia. Infect. Immun. 1998 66 : 5089 98.
20. Kundu N Yang Q Dorsey R Fulton AM. Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer. Int. J. Cancer 2001 93 : 681 6.
21. Molina MA Sitja-Arnau M Lemoine MG Frazier ML Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999 59 : 4356 62.
22. Fujita T Matsui M Takaku K et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res. 1998 58 : 4823 6.
23. Ristimaki A Honkanen N Jankala H Sipponen P Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997 57 : 1276 80.
24. Shamma A Yamamoto H Doki Y et al. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin. Cancer Res. 2000 6 : 1229 38.
25. Morris CD Armstrong GR Bigley G Green H Attwood SE. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am. J. Gastroenterol. 2001 96 : 990 6.
26. Tsujii M DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995 83 : 493 501.
27. Jones MK Wang H Peskar BM et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. 1999 5 : 1418 23.
28. Hida T Leyton J Makheja AN et al. Non-small cell lung cancer cyclooxygenase activity and proliferation are inhibited by non-steroidal anti-inflammatory drugs. Anticancer 1998 18 : 775 82.
29. Tjandrawinata RR Dahiya R Hughes-Fulford M. Induction of cyclooxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br. J. Cancer 1997 75 : 1111 18.
30. Boolbol SK Dannenberg AJ Chadbum A et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 1996 56 : 2556 60.
31. Hla T Neilson KO. Human cyclooxygenase-2 cDNA. Proc. NatlAcad. Sci. U S A 1992 89 : 7384 8.
32. Baeuerle PA. IkappaB-NF-kappaB structures: at the interface of inflammation control. Cell 1998 95 : 729 31.
33. Yin MJ Yamamoto Y Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I (kappa)B kinase-beta. Nature 1998 396 : 77 80.
34. Siebenlist U Franzoso G Brown K. Structure, regulation, and function of NF-kappaB. Annu. Rev. Cell Biol. 1994 10 : 405 55.
35. Wulczyn FG Krappmann D Scheidereit C. The NF-kappaB/Rel and IkappaB gene families: mediators of immune response and inflammation. J. Mol. Med. 1996 74 : 749 69.
36. Sovak MA Bellas RE Kim DW et al. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. JClin. Invest. 1997 100 : 2952 60.